Alexion (NASDAQ:ALXN) Waiting on Soliris

The promising potential of of Soliris in aHUS can't be included in the analysis of Alexion Pharmaceuticals (NASDAQ:ALXN) at this time, as there are still several steps to go through before it will be known if it'll be part of their product line.

Here's Needham's take on Soliris and Alexion:

"We are impressed by the efficacy of Soliris in this difficult-to-treat aHUS population, with no currently effective therapeutic options. We believe Soliris may have the potential to affect the underlying disease process and lead to better health outcomes and improved quality of life for these patients. Alexion is also conducting a pediatric study that may make Soliris available early in aHUS patients’ lives. With strong aHUS data in hand, we believe the Company is in discussion with the FDA regarding the regulatory pathway for Soliris for the aHUS indication. We await further updates on these discussions before we include the aHUS opportunity in our ALXN valuation."

Needham maintains their "Buy" rating on Alexion Pharmaceuticals. They closed Monday at $75.98, gaining $0.98, or 1.31 percent. Needham has a price target of $76 on them.